NEW YORK, May 29, 2019 /PRNewswire/ -- Hoth Therapeutics,
Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on unique
targeted therapeutics for patients suffering from indications such
as atopic dermatitis–also known as eczema–as well
as dermatological and chronic wound disorders, today announced
that its Chief Executive Officer, Mr. Robb
Knie, will be presenting at the 9th Annual LD Micro
Invitational Investor Conference. The event is being held at
Luxe Sunset Boulevard Hotel, located at 11461 Sunset Blvd,
Los Angeles, California.
Hoth Therapeutics is scheduled to present on Tuesday, June 4th, 2019. Conference
participation is by invitation only and registration is
mandatory.
About LD Micro
LD Micro was founded in 2006 with the
sole purpose of being an independent resource in the microcap
space. What started out as a newsletter highlighting unique
companies has transformed into an event platform hosting several
influential conferences annually (Invitational, Summit, and Main
Event). In 2015, LDM launched the first pure microcap index (the
LDMi), which covers stocks in North
America with market capitalizations between $50M-$300M to
exclusively provide intraday information on the entire sector. It
is a non-registered investment advisor. For more details, please
click here.
About Hoth Therapeutics, Inc.
Hoth Therapeutics, Inc.,
a Nevada corporation, is a biopharmaceutical company
focused on unique targeted therapeutics for patients suffering from
indications such as atopic dermatitis, also known as eczema. Hoth
has exclusive worldwide rights to the BioLexa Platform.
Forward Looking Statements
This press release includes
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements in this press release include, but are not limited to,
statements that relate to the advancement and development of the
BioLexa Platform, the commencement of clinical trials, the
availability of data from clinical trials and other information
that is not historical information. When used herein, words such as
"anticipate", "being", "will", "plan", "may", "continue", and
similar expressions are intended to identify forward-looking
statements. In addition, any statements or information that refer
to expectations, beliefs, plans, projections, objectives,
performance or other characterizations of future events or
circumstances, including any underlying assumptions, are
forward-looking. All forward-looking statements are based upon
Hoth's current expectations and various assumptions. Hoth believes
there is a reasonable basis for its expectations and beliefs, but
they are inherently uncertain. Hoth may not realize its
expectations, and its beliefs may not prove correct. Actual results
could differ materially from those described or implied by such
forward-looking statements as a result of various important
factors, including, without limitation, market conditions and the
factors described under the caption "Risk Factors" in Hoth's Form
10K for the period ending December 31, 2018, and Hoth's other
filings made with the Securities and Exchange Commission.
Consequently, forward-looking statements should be regarded solely
as Hoth's current plans, estimates and beliefs. Investors should
not place undue reliance on forward-looking statements. Hoth cannot
guarantee future results, events, levels of activity, performance
or achievements. Hoth does not undertake and specifically declines
any obligation to update, republish, or revise any forward-looking
statements to reflect new information, future events or
circumstances or to reflect the occurrences of unanticipated
events, except as may be required by law.
Contact
Investor Relations Contact:
Phone: (646) 756-2997
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hoth-therapeutics-to-present-at-the-9th-annual-ld-micro-invitational-investor-conference-on-june-4th-2019-300857875.html
SOURCE Hoth Therapeutics, Inc.